
Blockbuster Drugs Power Growth
Several key medicines fueled this strong performance:
- Entresto: $2.26 billion (+22%)
- Cosentyx: $1.53 billion (+18%)
- Kisqali: $956 million (+56%)
- Leqvio: $257 million (+72%)
Moreover, Novartis continued to focus on four high-impact areas like cardiovascular, immunology, neuroscience, and oncology. At the same time, it increased investments in cutting-edge platforms like gene therapy, radioligand therapy, and xRNA. The company also pushed for deeper market penetration in the US, China, Germany, and Japan.
Cash Flow Up, But Debt Grows
Free cash flow jumped 66% to $3.4 billion. However, net debt rose to $22.3 billion. This increase was mainly due to a $5.3 billion dividend payout, share repurchases, and investments in intangible assets.
Growth Outlook Remains Strong
Looking ahead, Novartis plans to accelerate growth through innovation and new product launches. It remains committed to R&D, digital technologies, and global expansion. Backed by strong cash generation and solid credit ratings, the company remains well-positioned for the rest of the year.
Vas Narasimhan, CEO of Novartis commented,
“Novartis has had a strong start to the year, delivering a +15% cc increase in sales and a +27% cc rise in core operating income in Q1. Our priority brands, including Kisqali, Kesimpta and Leqvio, continue to show strong momentum, which we anticipate will drive our growth through 2030 and beyond. We also achieved significant innovation milestones in the quarter, with new approvals for Pluvicto in the pre-taxane setting, Vanrafia for IgA nephropathy, and Fabhalta for C3G. Additionally, we completed global submissions for remibrutinib in CSU, the first indication for this promising pipeline-in-a-pill. We remain focused on advancing our leading pipeline and confident in achieving our growth outlook.”
Novartis on Track to Meet 2025 Sustainability Goals
Novartis is making steady progress toward its environmental goals. The company has already met its 2025 targets for reducing water use and waste. The Taskforce on Nature-related Financial Disclosures (TNFD) framework guides its broader sustainability efforts, showing a deep commitment to protecting the planet.

Big Cuts in Carbon Emissions
Novartis is cutting its carbon footprint aggressively. It plans to reach carbon neutrality in Scope 1 and 2 emissions by 2025. It follows the Science-Based Targets initiative and supports global efforts to limit climate change to 1.5°C.
By 2030, it aims to slash emissions by 90% from 2022 levels. The company also targets a 42% cut in Scope 3 emissions from suppliers and product use.
Scope Emissions
- In 2023, Scope 1 and 2 emissions totaled 298 tCO₂e, and Scope 3 emissions were 4,529 tCO₂e.
Most of the company’s environmental impact, about 95%, comes from direct operations such as land use, water use, and upstream emissions.

- Novartis intends to achieve net-zero emissions across its entire value chain by 2040.

Clean Energy Initiatives
The pharma giant plans to switch to 100% renewable electricity by 2025. To meet this goal, it’s investing in clean energy projects like biomass steam systems, electric boilers, solar thermal energy, and electric vehicles for its fleet.
The company also works closely with suppliers to add environmental standards to its contracts.
Water and Waste Goals Achieved
Novartis has reduced water usage at key sites, especially in water-stressed regions. It ensures no harmful impacts on water quality from its factories, labs, or suppliers.
On the waste front, the company plans to reduce disposal by 30%, making its operations cleaner and more efficient.
New Focus on Nature and Raw Materials
The company is expanding its efforts to protect nature and improve raw material sourcing. Some measures include biodiversity assessments at sites near sensitive ecosystems and creating nature management plans where needed.
Additionally, it’s shifting to more sustainable materials, starting with paper-based packaging.

Novartis is building a greener future through innovation, strong partnerships, and responsible action. From carbon cuts to water savings, the company is proving that environmental progress and business growth can go hand in hand.
- ALSO READ: Pfizer Plans to Reach Net Zero by 2040
AstraZeneca’s Q1 2025: Sales and Profit Soar on Strong Drug Performance
AstraZeneca posted a 10% rise in revenue at constant exchange rates, reaching $13.59 billion in Q1 2025, up from $12.68 billion last year. This growth came from strong demand for cancer and biopharma drugs across all key markets. The company’s net profit grew by 34% to $2.92 billion.

Tagrisso Leads the Pack
Tagrisso, AstraZeneca’s top lung cancer drug, generated $1.68 billion in sales. It was the company’s highest-selling medicine and the biggest driver of growth this quarter.
Furthermore, AstraZeneca saw strong R&D progress with five positive Phase III trials and 13 new drug approvals in major regions. Key oncology trials included DESTINY-Breast09, SERENA-6, and MATTERHORN.
Smart Deals to Fuel Long-Term Growth
In the first quarter of 2025, AstraZeneca made several smart business moves to strengthen its pipeline and technology base. It is heavily investing in cutting-edge technologies and expanding its global research and development (R&D) presence. These moves are aimed at driving long-term growth and staying ahead in the biopharma space.
JV for Vaccine Launch
- Launched a vaccine joint venture in China with BioKangtai and entered research partnerships with Syneron Bio and Tempus AI to boost innovation in cancer treatment.
Advancing Cell Therapy
- Proposed to acquire EsoBiotec to enter the in-vivo cell therapy space. EsoBiotec’s technology allows for “off-the-shelf” cell therapies, meaning ready-to-use treatments that don’t require custom patient cells.
Exploring Novel Drug Technologies
- Partnered with Harbour BioMed to develop multi-specific biologics, which can target multiple disease pathways at once.
- Teamed up with Syneron to create macro-cyclic peptides, a new type of molecule that could improve how drugs work in the body.
Improving Drug Delivery Methods
- Gained exclusive rights to ALT-B4 from Alteogen. This technology helps deliver drugs under the skin instead of by IV.
- Working on subcutaneous (under-the-skin) versions of several cancer drugs, making treatment faster and more comfortable for patients.
AstraZeneca’s Q1 2025 results show a strong push toward future-ready healthcare solutions. With new partnerships, acquisitions, and delivery tech, the company is setting itself up for long-term success in global markets.
Pascal Soriot, Chief Executive Officer, AstraZeneca, commented on the results:
“Our strong growth momentum has continued into 2025 and we have now entered an unprecedented catalyst-rich period for our company.
Already this year we have announced five positive Phase III study readouts, including most recently the highly anticipated DESTINYBreast09 for Enhertu, as well as SERENA-6 for camizestrant and MATTERHORN for Imfinzi; the latter two of these will feature in the ASCO 2025 plenary sessions, reflecting the significance of these data to the oncology community.
Our company is firmly committed to investing and growing in the US and we continue to benefit from our broad-based source of revenue and global manufacturing footprint, including eleven production sites in the US covering small molecules, biologics as well as cell therapy. Additionally, we have even greater US investment in manufacturing and R&D planned, leveraging our two large R&D sites in Gaithersburg MD and Cambridge MA. Overall, we are making excellent progress toward our ambition of eighty billion dollars in Total Revenue by 2030.”
AstraZeneca is Driving Sustainability with Science and Action
AstraZeneca is making major progress on its journey to a net-zero future. Through its ambitious “Ambition Zero Carbon” strategy, the company is investing $1 billion to cut emissions, switch to clean energy, and lead the healthcare sector toward a more sustainable model.
- AstraZeneca plans to go carbon negative by 2030.
Scope 1 and 2 Emissions
The company has significantly reduced its direct emissions. Gross Scope 1 and 2 GHG emissions (market-based) dropped from 200,838 tonnes in 2023 to 139,594 tonnes in 2024, highlighting substantial progress in cutting emissions across its operations.
Since 2015, AstraZeneca has reduced its Scope 1 and 2 greenhouse gas emissions by an impressive 77.5%. The company remains firmly on track to meet its ambitious target of a 98% reduction in these direct emissions by 2026.

Scope 3 Emissions
In 2024, AstraZeneca reported 5,897,822 tonnes of Scope 3 emissions, slightly down from 5,917,160 tonnes in 2023, showing a small but steady reduction in indirect emissions.
This progress reflects AstraZeneca’s strong commitment to climate action through clean energy use and operational efficiency.
Electric Fleets and Smarter Energy Use
- 63% of company vehicles are now fully electric; the goal is 100% by 2025
- 97% of the electricity used at company sites comes from renewable sources
- Energy consumption has dropped 20% since 2015
- Energy productivity has jumped 147%, showing better efficiency with less energy use
AstraZeneca’s progress shows how innovation, science, and sustainability can work hand-in-hand to build a healthier planet.

Clean Heat for Global Sites
AstraZeneca is replacing fossil fuels with clean, renewable heat at its sites around the world:
- US: Partnered with Vanguard Renewables to turn food and farm waste into renewable natural gas. Will heat all US R&D and manufacturing sites by 2026.
- UK: Working with Future Biogas to supply green gas to major UK sites (Macclesfield, Cambridge, Luton, Speke).
- China: Partnering with China Resources Gas to bring clean heat to its Wuxi plant, aiming to cut emissions in China by up to 80%. This is the first clean heat deal of its kind in the Chinese healthcare industry.
A Focus on Circular Solutions
AstraZeneca is cutting waste and reusing more materials. Instead of throwing things away, it focuses on recycling and the smarter use of resources.
The company is reducing single-use plastics. It’s also improving packaging to be more eco-friendly. In addition, AstraZeneca is working closely with suppliers to make greener choices.
Its factories now reuse materials and recycle more. As a result, operations are cleaner and more efficient. These efforts help protect the planet and inspire change across the healthcare industry.
So, Who Won the Profit and Net-Zero Game?
Novartis outperformed financially due to blockbuster drugs and strong cost discipline, while AstraZeneca led the way on sustainability, with steeper carbon cuts and near-complete renewable energy use.
The post Big Pharma Showdown: Novartis vs. AstraZeneca in Q1 2025 Profits and Emissions Cuts appeared first on Carbon Credits.
Carbon Footprint
Designing an Insetting Program: A Step-by-Step Playbook for Procurement
Insetting program design starts with your supplier map. The carbon claim comes much later.
Consider a coffee procurement team that funds a farm intervention before checking its sourcing data. The supplier aggregates coffee lots from several regions. The buyer lacks farm-level traceability. Another purchaser expects to report the same outcome. A more attractive project brochure solves none of these problems.
If the distinction between a value-chain intervention and a purchased credit is still open, read CCC’s Insetting vs Offsetting guide before you set the brief.
Insetting program design begins with the purchasing relationship and works outward. You need to decide 1) where an intervention belongs, 2) what business problem it addresses, 3) who pays for it, 4) how results will be measured, and 5) what the evidence will let you say about them. This five-step playbook turns that sequence into a procurement plan.
Step 1: Insetting program design starts with supplier mapping
Start with the commodities that matter most to your Scope 3 inventory and sourcing continuity. Ask finance for spend by supplier, sustainability for the emissions baseline, and category managers for origin and volume records. Then identify which suppliers can trace material to a jurisdiction, sourcing region, producer group, or individual land-management unit.
The level of traceability affects what you can account for. Under the GHG Protocol Land Sector and Removals Standard, the spatial boundary for purchased land-based products depends on the traceability associated with each volume. Farm-specific factors or removals require physical traceability through an acceptable chain-of-custody model. A contract with a tier-one trader, by itself, does not establish a link to the farms behind its deliveries.[1]
Build a first-pass table with five columns: commodity and annual volume; supplier and origin; current traceability level; land-use and production risks; and the business owner who can change the purchasing terms. Mark missing data plainly. A blank cell is cheaper to fix before a program starts than after a claim is drafted.
If your company sets an SBTi Forest, Land and Agriculture target (FLAG), keep its land-related target boundary separate from energy and industry emissions. The current FLAG guidance also requires relevant companies to assess primary deforestation-linked commodities in their value chains.[2]
Step 2: Choose a commodity and jurisdiction for a pilot
Select one supply corridor where the sourcing connection can be established and procurement has a reason to stay. A useful pilot has repeat purchases, suppliers willing to share records, an intervention matched to a diagnosed problem, and a defined plan to measure the result. Carbon potential alone is a poor selection rule if the supplier cannot deliver the crop your business needs.
Compare candidate regions on land-use risk, supplier concentration, local rights and tenure, the availability of baseline data, and exposure to drought, erosion, or forest conversion. Check the relevant legal requirements separately. A nature project does not satisfy a due-diligence obligation merely because it has a carbon method attached.
Consider a coffee buyer sourcing from two districts. In the first, producer-group records identify the farms, while recent dry seasons have increased rejected green coffee lots. In the second, deliveries pass through several intermediaries and farm origins are unknown. Pilot shade management in the first district, with local agronomic advice and quality checks built into the plan. The buyer can trace purchases there and test the intervention against a defined sourcing problem.
Use a short decision memo to record why the selected corridor beats the alternatives, what remains uncertain, and what would stop the pilot. That memo is the first control against a project drifting toward whatever happens to photograph well.
Step 3: Design the supplier engagement and commercial model
The intervention needs an owner on each side of the contract. Decide who supplies planting material or training, who maintains the practice, who bears the cost if a harvest disappoints, and how long the buyer expects to purchase from participating suppliers. Where smallholders participate, budget cash flow and technical support for practices that offer a later return.
Put these terms in a supplier agreement or pilot addendum. It should cover eligible farms and volumes, consent to data collection, access for monitoring, any land or carbon rights that matter, benefit sharing, and what happens if the purchasing relationship ends. Ask local counsel and producer representatives to review the arrangement. The Accountability Framework is a useful reference for supply-chain work involving forests, ecosystems, and human rights.[3]
Avoid assigning an automatic carbon benefit to the buyer. The contract should say which party has the right to report each outcome, how overlapping claims will be checked, and how any issued credits will be handled. A reduction reported in a buyer’s inventory cannot simply be sold for someone else’s offset claim without an accounting review. SBTi FLAG guidance excludes purchased credits used as offsets from near-term FLAG target achievement.[2]
Set commercial measures beside environmental ones: delivered volume, rejection rate, supplier retention, and procurement cost. They tell you whether the program works as a supply-chain investment, even if carbon accounting takes longer to resolve.
Step 4: Build monitoring, reporting, and verification before rollout
Agree on the baseline and data flow before paying for a full rollout. Identify the land units or sourcing regions in scope, the practices that change, the records suppliers already keep, and the additional measurements the program requires. Decide which data can come from field visits, transaction records, or remote sensing, and who checks each source.
For carbon, separate three questions. Did the practice happen? Did emissions or removals change under an applicable method? Can the buyer attribute a defensible share to its purchased goods without double counting? The GHG Protocol’s 2026 guidance includes dedicated chapters on spatial boundaries, data and methods, evaluating actions, credited outcomes, and assurance.[1] These are distinct jobs. A photograph of a planted tree answers only part of the first.
CCC’s MRV and Additionality article explains the separate evidence questions a project reviewer will ask.
Create an evidence file for every reporting period: dated supplier and farm records, purchase volumes, methods and emission factors, uncertainty, quality checks, and changes from the baseline. Specify who can challenge the data and how corrections are recorded. If a project also seeks credit certification, keep project accounting and corporate inventory accounting separate. The GHG Protocol says its land standard focuses on entity-level inventories and does not set the rules for credit certification.[4]
Start with the minimum viable measurement design that can survive review. Add complexity when the pilot tells you which data actually changes a decision.
Step 5: Decide what can be reported and claimed
Insetting program design needs reporting rules before the marketing copy. Procurement, sustainability, finance, and legal should agree on four distinct outputs: operational performance; observed land or nature outcomes; inventory effects, if the accounting criteria are met; and any separately issued credits. One dashboard can display them, but they should not share a single unqualified headline.
SBTi FLAG guidance allows certain land-based removals within a company’s operations or supply chain to contribute to FLAG pathways, subject to criteria including permanence, traceability, data quality, and allocation. It does not allow purchased offsets to meet near-term FLAG targets.[2] Eligibility therefore depends on evidence and the applicable target rules, not on calling an activity “insetting.”
Draft a claims register. For each proposed sentence, record the period, boundary, data owner, calculation method, reviewer, and whether the result is measured, estimated, or still a goal. If the evidence supports only “we funded a pilot with 200 farms,” say that. Do not turn a funding fact into a verified emissions reduction.
What good looks like by year three
Treat year three as a review point, not a promised payback date. A mature pilot should have mapped participating supply volumes, a stable supplier agreement, a repeatable data collection process, and a comparison of commercial and environmental results against the baseline. It should also have a documented answer for outcomes that cannot be included in the buyer’s inventory.
Scale only where the pilot improves a sourcing decision and the evidence can follow the product. If neither condition holds, redesign the intervention or change the corridor. A disciplined program can conclude that a site is unsuitable. That is useful procurement intelligence.
Discuss your insetting program with CCC
Carbon Credit Capital designs nature-based supply chain investments around sourcing needs and measurable sustainability outcomes. Schedule a consultation with our carbon and sustainability experts to map your tier-one supplier network, FLAG exposure, and first pilot decision.
Sources
[1] GHG Protocol, Land Sector and Removals Standard, version 1.1, and companion Guidance, June 2026: https://ghgprotocol.org/land-sector-and-removals-standard ; https://ghgprotocol.org/land-sector-and-removals-guidance
[2] Science Based Targets initiative, Forest, Land and Agriculture Science-Based Target-Setting Guidance, version 1.2, March 2026, especially pp. 16–17, 37, and 41: https://sciencebasedtargets.org/resources/files/SBTiFLAGGuidance.pdf
[3] Accountability Framework initiative, Accountability Framework and guidance for companies: https://accountability-framework.org/
[4] GHG Protocol, Frequently Asked Questions: Land Sector and Removals Standard, questions 10 and 18: https://ghgprotocol.org/blog/frequently-asked-questions-land-sector-and-removals-lsr-standard
Carbon Footprint
The Strategic Case for Nature-Based Carbon Investments
Nature-based carbon investments deserve consideration when they address a specific business dependency and produce outcomes you can measure. Imagine Moonbucks, a global coffee roaster planning next season’s espresso blend. It is considering natural Grade 4 coffee from Jimma, in southwestern Oromia, Ethiopia. Its sourcing decisions affect the roasting schedule and the cash tied up in coffee purchases. Moonbucks needs to understand which measures could protect that supply, what they would cost and how it would judge the results.
1. Define the sourcing problem before choosing a project
Moonbucks needs a dependable component for its espresso blend. Its procurement team wants continuity of volume and an agreed cup profile. Replacing a shipment at short notice could require new sample approval and changes to the blend, and given the schedules for cultivation, processing, and freight delivery, is practically impossible. Moonbucks needs to get this right, and its initial concern is inconsistent deliveries. It commissions an assessment of the supplying farms and post-harvest chain. The questions cover land condition, harvest availability and whether drying or storage problems are affecting saleable lots.
This distinction changes the investment brief. A tree-planting proposal cannot be assumed to fix drying problems. Better storage cannot restore eroded land. The team must establish which problem exists before selecting the response.
CCC’s guide to finding nature-based solutions in your supply chain explains where to look. Here, the next task is to turn a broad concern into a testable proposal.
2. Develop nature-based carbon investments around the actual supply chain
The assessment would trace Moonbucks’ purchases back through the exporter and supplying producer groups. Which farms supply the contracted lots? Who controls land-management decisions? How long does the buyer expect to maintain the purchasing relationship?
Furthermore, Jimma natural Grade 4 cannot be treated as interchangeable with every Ethiopian coffee. Moonbucks would need to test any substitute against its own blend and quality requirements.
Suppose Moonbucks’ assessment identifies an opportunity to maintain shade trees and restore vegetation along exposed streambanks. The IPCC describes agroforestry as a way to store carbon in vegetation and soil, with potential benefits for erosion control and water quality.1 Moonbucks would need local advice on species, growing conditions and maintenance before deciding how these measures fit its sourcing plan.
The proposal now has a defined sourcing connection and a candidate intervention. The next steps are to test its effect on production, assess carbon eligibility and build the financial case.
3. Compare the proposal with other ways to protect supply
WBCSD’s Nature-based Solutions Blueprint recommends comparing nature-based options with other responses across their benefits and costs.2 For Moonbucks, that means evaluating the landscape proposal alongside drying improvements, storage controls and alternative sourcing arrangements.
The product’s natural-process designation matters. Moonbucks should examine the drying and dry-milling chain alongside land conditions. Its team would check storage practices, contamination risks and incoming-lot quality to see whether problems arise before or after the coffee leaves the farms.
The revised proposal might combine land stewardship with separate post-harvest controls. Each component needs its own purpose and budget. A sustainability label should not obscure which activity is expected to solve which problem.
The project develops as the evidence improves. Its scope should follow the diagnosis rather than preserve the first idea unchanged.
4. Establish what the carbon outcome could count toward
Moonbucks’ sustainability team now tests the proposed carbon case separately from the sourcing case. Is the objective a measurable change in Moonbucks’ value-chain emissions, verified credits for separate voluntary use, or distinct outcomes under carefully defined arrangements?
Scope 3 covers value-chain emissions. A purchasing relationship alone does not prove that a farm intervention can be included in Moonbucks’ inventory. The team needs an applicable accounting method, defensible boundaries and evidence supporting attribution.
SBTi’s FLAG Guidance (forest, land and agriculture), version 1.2, says purchased credits used as offsets cannot meet near-term FLAG or energy and industry targets. Eligible land-based removals are subject to accounting requirements.3 Moonbucks needs to test its proposal against those rules before including an outcome in its targets.
For Moonbucks’ Jimma proposal, maintaining existing trees and establishing new vegetation could involve different carbon questions. Specialists must examine the baseline and additionality, meaning what changes because the project proceeds. They must also assess measurement and the risk that stored carbon is lost. CCC’s MRV and additionality article introduces those tests.
Until that work is complete, Moonbucks should not budget an assumed Scope 3 reduction or credit-sale receipt. Direct emissions reductions remain the priority.
5. Build a financial case that survives weaker assumptions
Moonbucks’ finance team would now build a multi-year budget. UNEP’s State of Finance for Nature 2023 compares current finance with the investment needed to meet climate, biodiversity and land-restoration goals.4 The company would cost its proposed activities, farmer participation and ongoing monitoring. Verification, where required, is a separate expense. Maintenance and responsibility for replacing failed plantings must remain visible after the initial establishment budget ends.
Operational benefits need equally careful treatment. If fewer rejected lots reduce emergency purchasing, count that saving once. Do not add “supply resilience” as another financial benefit when it represents the same avoided cost.
Moonbucks should compare a base case with slower benefits, higher implementation costs and no carbon revenue. It should also distinguish production outcomes from quality and shipment outcomes. A single good harvest would not prove that the landscape intervention caused better delivery performance.
A project can remain worth funding even when its carbon case needs more work. That decision must rest on the operational evidence and the company’s objectives, without unsupported environmental claims.
6. Fund a pilot with a clear expansion decision
Moonbucks’ first approval would fund a bounded pilot, rather than commit the entire sourcing program. Before spending, Moonbucks would agree on participating farms, responsibilities and the evidence needed at review.
Its scorecard could track farmer participation, implementation costs and plant survival, alongside accepted coffee volumes and lot-quality results. Carbon measurements would follow the selected method. Farm-level traceability must connect the intervention to the actual sourcing relationship.
Suppose Moonbucks’ review later finds that storage changes explain most quality improvements, while the land measures need longer observation. Those findings would shape the next decision: expand the proven component, adjust the landscape work or pause further spending. They would not justify crediting all improvements to tree planting.
This gives nature-based carbon investments a practical place in a multi-year strategy. Funding increases as the evidence supports it, and the project can change direction before a larger commitment.
Discuss a sourcing opportunity with CCC
Carbon Credit Capital’s nature-based supply-chain investment service uses its Dual-Value Model to examine supply-chain economics alongside potential sustainability outcomes.
Schedule a consultation to discuss your sourcing exposure and the questions to resolve before allocating capital.
Sources
- Intergovernmental Panel on Climate Change (IPCC), Climate Change 2022: Mitigation of Climate Change, Chapter 7, Agriculture, Forestry and Other Land Uses, section 7.4.3.3 (Agroforestry).
- World Business Council for Sustainable Development (WBCSD), Nature-based Solutions Blueprint, 5 June 2024.
- Science Based Targets initiative (SBTi),

